Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding agent, has proven to be an effective monotherapy for metastatic melanoma and has shown antitumor activity in trials when administered with other therapeutic agents. We hypothesized that the combination of ipilimumab with chemotherapeuti...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Berlin Heidelberg
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755230/ |